Repotrectinib is a newer ROS1 TKI that is considered less susceptible to ROS1 resistance mechanisms among patients with ROS1+ aNSCLC and more active in the CNS; deep reductions in tumor volume and durable clinical activity have been observed, including in brain lesions [19]. The gene discussed is ROS1; the disease is neoplasm.